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Accrual target was 20 patients for each group with a planned
interim analysis afterw10 patients. For each pilot patient, a
control was randomly selected from 2013; controls were
matched by age, graft source, diagnosis and cell dose.
Implementation of the pilot was the effort of a multi-disci-
plinary team including physicians, mid-level providers,
nurses, clinical pharmacists, data and quality assurance
personnel.
Findings: For the auto and allo MAC groups, interim analysis
revealed that omission of G-CSF led to longer LOS and longer
time to neutrophil engraftment (see Table). The interim
analysis of the allo RIC group appears to be comparable for
the length of stay and neutrophil engraftment.
Discussion: Any cost savings of not using G-CSF are likely to
be offset by the longer duration of post-transplant hospital-
ization and possible increased risks due to longer periods of
neutropenia. Based on our ﬁndings, the pilot has been dis-
continued for auto and allo MAC transplants, where we will
continue to use G-CSF starting on Day +5 to promote
engraftment. This pilot will accrue the planned 20 patients
for allogeneic RIC patients before a ﬁnal analysis is per-
formed.PHARMACY
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Background: Methotrexate (MTX) is routinely utilized for
prophylaxis of graft versus host disease (GVHD). MTX may
contribute to mucositis and delayed engraftment. Severe
mucositis results in MTX dose reduction, holding day +6 and/
or day + 11, addition of folinic acid (FA), or the use of dexa-
methasone. Delivery of day +11 MTX has been reported to be
important in reducing the risk of aGVHD. FA administration
after MTX doses has been shown to reduce MTX toxicity. In
an effort to reduce the incidence of mucositis to improve the
likelihood of administering day +11 MTX and to provide a
consistent treatment guideline, the Hematopoietic Cell
Transplant (HCT) program director enlisted the help of the
HCT pharmacist to review the data and recommend
guidelines.
Methods: A review of the literature for post-MTX FA use was
performed and presented at an HCT program education
session. FA dosing, time of initiation post MTX, schedule and
number of doses were discussed. The HCT providers agreed
to follow the HCT pharmacist recommendation of FA 10mg/
m2 IV every 6 hours x 3 doses starting 12 hours after each
MTX dose (day +1, +3, +6 and +11) with myeloablative (MA)
conditioning regimens. All patients received tacrolimus. Data
was retrospectively collected in 2013 after the FA guideline
was adopted and compared to consecutive patients receiving
MA regimens from a control group in 2012. The primary
endpoint was administration of full dose day +11 MTX. Sec-ondary endpoints were rates of aGVHD, cGVHD, total
parenteral nutrition (TPN) use, patient controlled analgesia
(PCA) use, transplant-related mortality (TRM), relapse and
overall survival (OS).
Results: The FA group consisted of 27 patients while there
were 31 in the control. Patients in the FA group were more
likely to receive full dose day +11 MTX as compared to con-
trol, 85.2% vs 48.4% (p¼0.0025) and were less likely to
require PCA, 63% vs. 87.1% (p¼0.03). There was no signiﬁcant
difference in rates of TPN use (48.2% vs. 58.1%), grade II-IV
aGVHD at day 100 (50.4% vs. 30.5%), cGVHD (19.9% vs. 27.7%),
cumulative incidence of relapse (10.8% vs. 8.6%), TRM at 1
year (13.1% vs.19.5%) and OS at 1 year (77.9% vs. 75.9%) for the
FA group and control, with a median follow-up of 465 days
and 670 days, respectively.
Discussion: Patients experienced less mucositis and were
more likely to receive full dose day + 11 MTX after
implementation of the FA guideline. This was also sup-
ported by a statistically signiﬁcant decrease in PCA use.
Other endpoints trended in a favorable direction, but did
not reach statistical signiﬁcance. The development and
utilization of the program guideline improved consistency
of care, improved staff satisfaction and decreased patient
discomfort. HCT pharmacists play an important role in the
review of literature and development of program guide-
lines.125
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Background: Anti-thymocyte globulin (ATG) is often
incorporated into allogeneic stem cell transplant (alloHCT)
conditioning regimens to prevent graft-versus-host disease
(GVHD). Literature regarding the effect of ATG on outcomes
is mixed; some data suggests an improvement in GVHD
control with ATG use, but other data shows a reduction in
overall survival, particularly in the reduced intensity
setting. This study evaluates the impact of ATG on infection,
GVHD, relapse, and mortality rates in adult alloHCT
patients.
Methods: A retrospective review of 250 adult alloHCT
patients at our institution (125 unrelated/mismatched
donor recipients received ATG, 125 matched related do-
nors did not) between 2006 and 2013 was performed.
Charts were reviewed for ATG use, demographics, in-
fections (bacterial, viral, fungal), infection source, GVHD,
day-180 relapse, and day-180 mortality. The primary
endpoint was infection rate; secondary endpoints included
mortality and GVHD.
Results: Factors with signiﬁcant impact on infection inci-
dence were conditioning type (Myeloablative (MAC) >
Reduced Intensity (RIC), p¼0.0105), age (p¼0.0245), and
use of ATG (p¼0.0185). MAC was associated with greater
Figure 1. Time to mortality
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2 infections, p¼0.0001). Infection incidence was signiﬁ-
cantly increased in patients receiving ATG compared to
those not receiving ATG (median 3 vs. 2, p¼0.0003). The
relative increase in infections with ATG was more pro-
nounced in RIC (+ATG median 3 vs eATG median 1) than in
MAC (+ATG median 4 vs. eATG median 3). In both RIC and
MAC, ATG use was associated with increased numbers of
CMV (112 vs. 61), HHV6 (47 vs. 13), and HSV (32 vs. 8)
infections. The relative increase in infection incidence for
+ATG patients in RIC (CMV 2.5-fold, HHV6 10.5-fold, HSV
6.5-fold increase) was greater than the increase seen for
+ATG patients in MAC (CMV 1.46-fold, HHV6 2.36-fold, HSV
3.17-fold increase).
Similar rates of severe (grade 3-4) aGVHD were observed
in +ATG patients compared to eATG patients (17.5% vs.
14.95%, p¼0.72) through day 180, indicating a potential
protective effect of ATG in unrelated/mismatched trans-
plants. In RIC, a nonsigniﬁcantly greater proportion of +ATG
patients developed severe aGVHD (19.4%) compared toeATG
patients (12.9%).
The rates of relapse/death were not different between
ATG groups (29.91% for eATG and 39.68% for +ATG), and
groups had similar mean times to relapse (148 days foreATG
and 138 days for +ATG). At 180 days, survival was 83.2% for
eATG and 71.4% for +ATG (p¼0.0426).
Conclusion: Our study demonstrates that ATG use in-
creases infection rates in alloHCT patients, with greater
impact in the RIC setting. Although relapse rates were
similar between groups, the 180-day mortality for +ATG
was signiﬁcantly greater than eATG, suggesting that in-
fectious complications may impact mortality associated
with ATG.Figure 2. Time to relapse126
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Background: Current literature supports the use of he-
matopoietic stem cell transplants (hSCT) over salvage
chemotherapy for patients with lymphoma who have
recurrent disease or are at high risk of relapse. Few studies
have been published directly comparing preparative regi-
mens, thus most institutions select regimens based on
associated toxicities. At our institution, Busulfan/Cyclo-
phosphamide (Bu-Cy) was historically used as the prepar-
ative regimen for patients with lymphoma. A transition was
made in 2009 to favor the theoretically less toxic Carmus-
tine/Etoposide/Cyclophosphamide (CBV) regimen for older
patients.
Objective: Compare the tolerability and efﬁcacy of Bu-Cy and
CBV as they pertain to autologous stem cell transplants in
older patients.
Methods: We report a retrospective review of institutional
data evaluating the safety and efﬁcacy of Bu-Cy and CBV in
patients with lymphoma receiving an autologous hSCT be-
tween January 2005 and January 2014. Patients were
excluded if they were less than 60 years of age. The primary
outcomewas the incidence of grade 3 and 4 toxicities per theCTCAE v4.03. Secondary outcomes included progression-free
and overall survival.
Results: Seventy-ﬁve patients were available for analysis,
23 received Bu-Cy and 52 received CBV. Patients who
received Bu-Cy experienced an average of 1.6 severe or life-
threatening toxicities per patient compared with 1.7 for
those who received CBV. There was no difference in pro-
gression-free (BuCy 86% vs CBV 95%) or overall survival
(BuCy 96% vs CBV 94%) at 60 days; however, there was a
trend toward increased progression-free survival (BuCy31%
vs CBV 68%) at three years Figure 1) and this trend was
supported by the increased time to relapse (BuCy 22.7 vs
CBV 61.2 months) (Figure 2).
Conclusions: This review demonstrates no difference in
terms of tolerability or efﬁcacy between Bu-Cy and CBV;
however, there is a trend towards improved relapse free
survival with CBV. Future studies are needed to compare
other utilized preparative regimens.127
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